Page 4 - Eric Widera News Today

WASHINGTON - Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening - by about four to seven months, researchers reported Monday. Eli Lilly and Co. is seeking Food and ...

Breakthrough new drugs that clear amyloid beta plaques from the brain are shaking up the field of Alzheimer's disease research.

MONDAY, July 24, 2023 (HealthDay News) -- Breakthrough new drugs that clear amyloid beta plaques from the brain are shaking up the field of Alzheimer’s disease research.

Scientists say while these drugs may mark a new era in Alzheimers therapy, huge questions remain about which patients should try them and how much benefit theyll really notice.

Life expectancy increasingly figures into calculations about whether screenings and treatments are appropriate. Here’s how to find out yours.

WASHINGTON—Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening—by about four to seven months, researchers reported Monday. Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease—after the recently…

New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening. Patients given monthly infusions of Eli Lilly and Co.'s donanemab declined about four to seven months more slowly than those given dummy infusions in a large study. If U.S. regulators approve, the drug would be only the second Alzheimer's treatment convincingly shown to delay the mind-robbing disease — after rival Leqembi. Both drugs pose a serious safety concern — brai...

Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday. Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease — after the recently approved…

New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months — but comes with safety risks.

Eli Lilly's experimental Alzheimer's drug donanemab​ can modestly slow the worsening of the disease by about four to seven months, according to researchers.